CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Frequently asked questions
What sector does CanBas Co Ltd (4575) operate in?
CanBas Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CanBas Co Ltd (4575) current stock price?
As of the latest data, CanBas Co Ltd stock price is ¥721, with a previous close of ¥735. CanBas Co Ltd lost -¥14 in the last trading session, representing a -1.9% loss.
What is CanBas Co Ltd (4575) current market capitalization?
CanBas Co Ltd market cap is approximately 14.21 billion.
What is CanBas Co Ltd (4575) Earnings Per Share (EPS)?
The trailing EPS is -¥66.
What is CanBas Co Ltd (4575) EBITDA?
CanBas Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -442.12 million.
Does CanBas Co Ltd (4575) pay dividends?
No. CanBas Co Ltd does not pay a dividend.
What is CanBas Co Ltd (4575) beta (volatility) score?
CanBas Co Ltd has a beta of -0.800, indicating lower volatility than the overall market.